Factor D inhibitor (oral complement inhibitor, adjunctive)
Danicopan
Brand names: Voydeya
Adult dose
Dose: 150mg PO TDS, increased to 200mg TDS if needed
Route: Oral
Frequency: TDS
Clinical pearls
- NICE TA evaluation: paroxysmal nocturnal haemoglobinuria with extravascular haemolysis on C5 inhibitor (eculizumab/ravulizumab) — adjunctive
- Specialist haematology centre
- Meningococcal vaccination prerequisite
Contraindications
- Unresolved Neisseria meningitidis infection
- Hypersensitivity
Side effects
- Headache
- Diarrhoea
- Nausea
- Increased ALT
- Infections (encapsulated bacteria)
Interactions
- Strong CYP3A4 inhibitors/inducers
Monitoring
- Hb
- Reticulocytes
- LFTs
- Infection signs
Reference: BNF; NICE TA evaluation; SmPC; https://bnf.nice.org.uk/drugs/danicopan/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- DOAC Score for Selecting Direct Oral Anticoagulant in Non-Valvular AF · Anticoagulation
- SMART Risk Score for Recurrent CVD · Cardiovascular Risk
- PCSK9 Inhibitor Eligibility Assessment · Lipid Management
- Insulin Correction Factor (ICF/ISF) · Insulin Management
- R Factor for Drug-Induced Liver Injury (DILI) · Liver Disease
- Immune-Related Adverse Events (irAE) -- GI Toxicity Colitis Grading · Oncology-Related GI
Pathways
- Major Haemorrhage / Massive Transfusion · BCSH; RCOA; RCEM; RCS — BCSH Guidelines
- Anaemia Investigation · BSH / NICE
- Splenomegaly Workup · BSH; BMJ Best Practice
- Deep Vein Thrombosis Diagnosis and Treatment · NICE CG144 / NICE NG158
- Sickle Cell Crisis · BSH 2021 / BCSH
- Neutropenic Sepsis · NICE CG151 2012 / ESMO